Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ABSI
Absci Corporation (ABSI) EV/Sales
As of 16 October 2026, Absci Corporation (ABSI) trades at a EV/Sales of 704×. Over the past ten years it has ranged from −6.7× (May 2023) to 1,043× (July 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 119× | 228.88% |
| FY2024 | 36.3× | (11.24%) |
| FY2023 | 40.9× | 525.61% |
| FY2022 | 6.5× | (79.33%) |
| FY2021 | 31.6× | (59.99%) |
| FY2020 | 79.0× | 0.00% |
| FY2019 | 79.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1,040× | 472.53% |
| Mar 2026 | 182× | 52.35% |
| Dec 2025 | 119× | 24.54% |
| Sep 2025 | 95.8× | 101.80% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MAZE Maze Therapeutics, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.7× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.5× |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| NTLA Intellia Therapeutics, Inc. compare | 18.3× |
| QURE uniQure N.V. compare | 36.8× |
| ABSI Absci Corporation | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)